SCHEMBL25210585

SCHEMBL25210585

CC(C)(C)OC(=O)NCc1ccc(C(=O)O)c(CO)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.39
RPS6KA1 Q15418 1/20 0.39
KDM4A O75164 1/20 0.38
NAMPT P43490 1/20 0.36
CTSS P25774 3/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
GRM2 Q14416 1/20 0.35
EPHX2 P34913 2/20 0.35
NR1H4 Q96RI1 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CTSK P43235 2/20 0.35
EPAS1 Q99814 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CA7 P43166 1/20 0.34
CA14 Q9ULX7 1/20 0.34
PTPN11 Q06124 1/20 0.34
HDAC10 Q969S8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14940927 0.87 KCNA5 (0.42) KCNA5RPS6KA1KDM4ANAMPTCTSS
SCHEMBL25247489 0.86 KCNA5 (0.40) KCNA5RPS6KA1KDM4ANAMPTCA12
SCHEMBL12234545 0.83 RPS6KA1 (0.43) KCNA5RPS6KA1KDM4ANAMPTCA12
SCHEMBL12231435 0.78 ATR (0.42) KCNA5RPS6KA1KDM4ANAMPTCA12
SCHEMBL28215080 0.78 KDM4A (0.42) KCNA5RPS6KA1KDM4ACTSSGRM2
SCHEMBL1654700 0.78 KDM4A (0.42) KCNA5RPS6KA1KDM4ACTSSGRM2
SCHEMBL30480695 0.78 RPS6KA1 (0.41) KCNA5RPS6KA1KDM4ACTSSCA12
SCHEMBL28212129 0.78 RPS6KA1 (0.41) KCNA5RPS6KA1KDM4ACTSSCA12
SCHEMBL28255694 0.76 KCNA5 (0.50) KCNA5RPS6KA1KDM4ANAMPTCTSS
SCHEMBL25249874 0.76 EPHX2 (0.38) KCNA5KDM4ANAMPTCTSSGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116457344-B Low molecular weight protein degradation agent and application thereof 凯普托尔治疗学股份有限公司 2026-05-12 CN disclosed
US-20240294489-A1 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
CN-116457344-A Low molecular weight protein degradation agent and application thereof 凯普托尔治疗学股份有限公司 2023-07-18 CN disclosed
EP-4188373-A1 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS Captor Therapeutics S.A. (PL) 2023-06-07 EP disclosed
WO-2022029138-A1 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS CAPTOR THERAPEUTICS S.A. (PL) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294489-A1 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS MMP2, PSME2, PSME1 KCNA5 4736/4885RPS6KA1 1580/4885KDM4A 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.